AstraZeneca to Invest $820M in Ontario's Life Sciences Sector

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, recently announced a C$820 Million (US$570M) investment in Canada, to expand the company’s research and development (R&D) facilities in Mississauga and relocate the company’s Canadian headquarters to a larger, state-of-the-art office. The investment will create over 700 new, good-paying jobs across Ontario’s life sciences sector and further establish the province as a global biomanufacturing and life sciences hub, leading in the development, commercialization and early adoption of innovative health products and services.